<div id="readability-page-1"><p>AtriCure (NASDAQ:ATRC - Get Free Report) is anticipated to release its  Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect AtriCure to post earnings of ($0.04) per share and revenue of $140.50 million for the quarter. Individuals are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.</p><h2>AtriCure Stock Down 0.5%</h2><p>Shares of NASDAQ:ATRC opened at $36.92 on Tuesday. The company has a current ratio of 3.87, a quick ratio of 2.85 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $39.34 and a two-hundred day simple moving average of $36.80. AtriCure has a 12-month low of $28.29 and a 12-month high of $43.18. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -60.52 and a beta of 1.42. </p><h2>Analysts Set New Price Targets</h2><p>ATRC has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their price target on shares of AtriCure from $53.00 to $64.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, October 30th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of AtriCure in a report on Wednesday, January 21st. Zacks Research upgraded shares of AtriCure from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, January 6th. Citigroup  reaffirmed a &#34;market outperform&#34; rating on shares of AtriCure in a report on Thursday, October 30th. Finally, JPMorgan Chase &amp; Co. lifted their target price on AtriCure from $42.00 to $48.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, December 16th. One analyst  has rated the stock with a Strong Buy rating, ten have issued  a Buy rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $52.44.</p><p><b>View Our Latest Analysis on AtriCure</b></p><h2>Insiders Place Their Bets</h2><p>In related news, insider Justin J. Noznesky sold 5,166 shares of the business's stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total value of $192,640.14. Following the completion of the transaction, the insider owned 78,798 shares of the company's stock, valued at $2,938,377.42. The trade was a 6.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Sven Wehrwein sold 5,033 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $37.32, for a total value of $187,831.56. Following the sale, the director directly owned 34,374 shares in the company, valued at $1,282,837.68. This trade represents a 12.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 18,166 shares of company stock worth $676,378 in the last three months. Corporate insiders own  3.50% of the company's stock. </p><h2>Institutional Investors Weigh In On AtriCure</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geneos Wealth Management Inc. purchased a new position in shares of  AtriCure during the second quarter worth $37,000.  Strs Ohio acquired a new position in  AtriCure in the 1st quarter valued at $158,000.  Tower Research Capital LLC TRC lifted its stake in shares of  AtriCure by 502.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,492 shares of the medical device company's stock worth $180,000 after buying an additional 4,581 shares in the last quarter.  State of Tennessee Department of Treasury acquired a new position in  AtriCure during the second quarter worth $184,000.  Finally, Quadrant Capital Group LLC acquired a new position in  AtriCure in the 3rd quarter valued at about $198,000. 99.11% of the stock is currently owned by institutional investors and hedge funds. </p><h2>AtriCure Company Profile</h2> (Get Free Report)<p>AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.  </p><p>The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.</p><h2>See Also</h2><ul><li>Five stocks we like better than AtriCure</li><li>The buying spree that no one is talking about</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>How to collect $500-$800 weekly (BlackRock's system)</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Your Bank Account Is No Longer Safe</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRSQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRSQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AtriCure Right Now?</h2><p>Before you consider AtriCure, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AtriCure wasn't on the list.</p><p>While AtriCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ATRC

<p>AtriCure (NASDAQ:ATRC) is set to release its Q4 2025 earnings on February 17, with analysts predicting a loss of $0.04 per share and revenue of $140.50 million. The stock is currently down 0.5%, trading at $36.92. Recent analyst reports have varied, with Canaccord Genuity raising its price target to $64.00 and Weiss Ratings maintaining a 'sell' rating. Insiders have sold shares recently, and institutional investors hold 99.11% of the stock. AtriCure specializes in medical devices for treating atrial fibrillation.</p>

AtriCure (ATRC) Projected to Post Earnings on Tuesday